Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: A randomized controlled trial

Archives of Gynecology and Obstetrics

Volumn 289, Issue 1, 2014, Pages 193-200

  Onalan, Gogsen ^a   Gulumser, Cagri ^a   Mulayim, Baris ^a   Dagdeviren, Atilla ^a   Zeyneloglu, Hulusi ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Amifostine; Endometriosis; Leuprolide; NAC; TNF alpha

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ASIST AMPUL; ETHYOL FLACON; LEUPRORELIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIOSIS; FEMALE; LOADING DRUG DOSE; NONHUMAN; OVARY; PERITONEUM; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RAT; REMISSION; SINGLE DRUG DOSE; ABDOMINAL WALL; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; ENDOMETRIUM; PERITONEAL DISEASES; RANDOMIZATION; TREATMENT OUTCOME; WISTAR RAT;

ABDOMINAL WALL; ACETYLCYSTEINE; AMIFOSTINE; ANIMALS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; LEUPROLIDE; PERITONEAL DISEASES; PERITONEUM; RANDOM ALLOCATION; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84891873935     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2963-0     Document Type: Article

References (51)

1. Wheeler JM (1989) Epidemiology of endometriosis-associated infertility. J Reprod Med 34:41-46 (Pubitemid 19064694)
2. Matorras R, Rodiquez F, Pijoan JI, Ramon O, Gutierrez DT (1995) Rodriguez- Escudero F Epidemiology of endometriosis in infertile women. Fertil Steril 63:34-38
3. Portz DM, Elkins TE, White R, Warren J (1991) Adadevoh S and Randolph J Oxygen free radicals and pelvic adhesion formation: I. Blocking oxygen free radical toxicity to prevent adhesion formation in an endometriosis model. Int J Fertil 36:39-42
4. Murphy AA, Palinski W, Rankin S, Morales AJ, Parthasarathy S (1998) Evidence for oxidatively modified lipid-protein complexes in endometrium and endometriosis. Fertil Steril 69:1092-1094 (Pubitemid 28274899)
5. Van Langendonckt A, Casanas-Roux F, Donnez J (2002) Oxidative stress and peritoneal endometriosis. Fertil Steril 77:861-870 (Pubitemid 34497149)
6. Jackson LW, Schisterman EF, Dey-Rao R, Browne R, Armstrong D (2005) Oxidative stress and endometriosis. Hum Reprod 20:2014-2020 (Pubitemid 40932392)
7. Zeller JM, Henig I, Radwanska E, Dmowski WP (1987) Enhancement of human monocyte and peritoneal macrophage chemiluminescence activities in women with endometriosis. Am J Reprod Immunol Microbiol 13:78-82 (Pubitemid 17075991)
8. Murphy AA, Santanam N, Parthasarathy S (1998) Endometriosis: a disease of oxidative stress? Semin Reprod Endocrinol 16:263-273 (Pubitemid 29201008)
9. Murphy AA, Palinski W, Rankin S, Morales AJ, Parthasarathy S (1998) Macrophage scavenger receptor(s) and oxidatively modified proteins in endometriosis. Fertil Steril 69:1085-1094 (Pubitemid 28274898)
10. Vinatier D, Cosson M, Dufour P (2000) Is endometriosis an endometrial disease ? Eur J Obstet Gynecol Reprod Biol 91:113-125 (Pubitemid 30408318)
11. ®): pharmacocinetic and pharmacodynamic effects in vivo. Eur J Cancer 32:26-30
12. ValerIa S, FrancIs J (1999) GIles the potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84:1035-1042
13. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760 (Pubitemid 13030692)
14. Slusser SO, Grotyohann LW, Martin LF (1990) Scaduto RC glutathione catabolism by the ischemic rat kidney. Am J Physiol 258:1546-1553
15. Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, Agarwal A (2002) Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 17:426-431 (Pubitemid 34168452)
16. Iwabe T, Harada T, Terakawa N (2002) Role of cytokines in endometriosis-associated infertility. Gynecol Obstet Invest 53:19-25 (Pubitemid 34136828)
17. Küpker W, Felberbaum R, Bauer O, Diedrich K (1996) Significance of tumour necrosis factor alpha (TNF-alpha) in endometriosis. Geburtshilfe Frauenheilkd 56:239-242 (Pubitemid 26189279)
18. Richter ON, Dorn C, Rösing B, Flaskamp C, Ulrich U (2005) Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet 271:143-147 (Pubitemid 40476246)
19. Galo S, Zúbor P, Szunyogh N, Kajo K, Macháleková K, Biringer K, Visnovský J (2005) TNF-alpha serum levels in women with endometriosis: prospective clinical study. Ceska Gynekol 70:286-290 (Pubitemid 41098034)
20. Yavuz E, Oktem M, Esinler I, Arat Toru S, Zeyneloglu HB (2007) Genistein causes regression of endometriotic implants in the rat model. Fertil Steril 88:1129-1134 (Pubitemid 47513051)
21. Dogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S, Saatli B (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 182:1115-1120 (Pubitemid 39335926)
22. Capizzi RL (1996) Amifostine: the preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23:2-17 (Pubitemid 26321666)
23. McCauley DL (1997) Amifostine: a novel cytoprotective agent. Cancer Pract 5:189-191 (Pubitemid 27224448)
24. Foster-Nora JA, Siden R (1997) Amifostine for protection from antineoplastic drug toxicity. Am J Health-Syst Pharm 54:787-800 (Pubitemid 27174802)
25. Valeriote F, Tolen S (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331 (Pubitemid 13205920)
26. Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SN, Culo F (1980) Treatment of tumors with the combination of WR-2721 and cis- dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42:574-585 (Pubitemid 11240538)
27. Yuhas JM, Culo F (1980) Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 64:57-64 (Pubitemid 10125454)
28. Griggs JJ (1998) Reducing the toxicity of anticancer therapy: new strategies. Leuk Res 22:27-33 (Pubitemid 28391353)
29. ®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer 32:17-20
30. Kemp G, Rose P, Lurain J et al (1996) Amifostine pretreatment for protection against cyclophosphamideinduced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112 (Pubitemid 26230113)
31. Dunn TA, Schmoll H-J, Grunwald V, Bokemeyer C, Casper J (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs 7:795-799 (Pubitemid 26388772)
32. Aviles A, Diaz-Maqueo JC, Talavera A, Garcia EL, Guzman R, Nambo MJ (1997) Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer 33:1323-1325 (Pubitemid 27359654)
33. Paine GD, Taylor CW, Lopez MHA, Johnson CS, Capizzi RL (1996) Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 2:35-39 (Pubitemid 26321669)
34. MarzatIco F, Porta C, MoronI M, BertorellI L, BorasIo E, FInottI N, Pansarasa O, Castagna L (2000) In vitro antioxidant properties of amifostine (WR-2721, Ethol). Cancer Chemother Pharmacol 45:172-176 (Pubitemid 30090249)
35. OhnIshI ST, OhnIshI T, GlIck JH, ScheIn PS (1992) In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 33:419
36. Orditura M, Devita F, Roscigno A (1999) Amifostine: a selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity. Oncol Rep 6:1357-1362
37. StankIewIcz A, Skrzydlewska E, MakIeła M (2002) Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. Drug Metab Drug Interact 19:67-82 (Pubitemid 36537996)
38. Stankiewicz A, Skrzydlewska E, Sulkowska M, Sulkowski S (2002) Effect of amifostine on lung oxidative stress after cyclophosphamide therapy. Bull Vet Pulawy 46:87
39. Stankiewicz E, Skrzydlewska E (2005) Amifostine antioxidant effect on serum of rats treated with Cyclophosphodamide A. Pol J Environ Stud 14:341-346 (Pubitemid 40659568)
40. Shaw LM, Glover D, Turrisi A et al (1988) Pharmacokinetics of WR-2721. Pharmacol Ther 39:195-201
41. Shaw LM, Turrisi AT, Glover DJ et al (1986) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12:1501-1504 (Pubitemid 16030648)
42. Korst AEC, Gall HE, Vermorken JB, van der Vijgh WJF (1996) Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 39:162-166 (Pubitemid 26400676)
43. Utley JF, Seaver N, Newton GL, Fahey RC (1984) Pharmacokinetics of WR-1065 in mouse tissue following treatmentwith WR-2721. Int J Radiat Oncol Biol Phys 10:1525-1528 (Pubitemid 14018246)
44. Shaw LM, Bonner H, Lieberman R (1996) Pharmacokinetic profile of amifostine. Semin Oncol 23:18-22 (Pubitemid 26321667)
45. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM (2002) Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol 29(6 Suppl 19):2-8 Review (Pubitemid 36173239)
46. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM (2003) Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 57(3):794-802 (Pubitemid 37194307)
47. Elas M, Parasca A, Grdina DJ, Halpern HJ (2003) Oral administration is as effective as intraperitoneal administration of amifostine in decreasing nitroxide EPR signal decay in vivo. Biochim Biophys Acta 1637:151-155 (Pubitemid 36287409)
48. Ocal K, Avlan D, Cinel I, Unlu A, Ozturk C, Yaylak F, Dirlik M, Camdeviren H, Aydin S (2004) The effect of N-acetyl cysteine on oxidative stress in intestine and bacterial translocation after thermal injury. Burns 30:778-784 (Pubitemid 39536043)
49. Conesa LE, Valero F, Nadal JC et al (2001) N-acetyl-l-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol 281:730-737
50. Sehirli AO, Sener G, Satiroglu H, Ayanoglu-Dulger G (2003) Protective effect of N-acetyl cysteine on renal ischemia/reperfusion injury in the rat. J Nephrol 16:75-80
51. Sato Hideyo, Tamba Michiko, Ishii Tetsuro, Bannai Shiro (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 27:11455-11458 (Pubitemid 29197795)